PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media288619ArticlesСтатьиResearch ArticleALTERNATIVE THERAPY OF FUNCTIONAL GASTROINTESTINAL DISEASESАЛЬТЕРНАТИВНАЯ ТЕРАПИЯ ФУНКЦИОНАЛЬНЫХ ЗАБОЛЕВАНИЙ ЖЕЛУДОЧНО-КИШЕЧНОГО ТРАКТАPlotnikovaE. YuПлотниковаЕ. Ю

MD, Prof. at the Department of Training of Doctors of Primary Health Care, Head of the Course of Clinical Gastroenterology

д.м.н., проф. кафедры подготовки врачей первичного звена здравоохранения, рук. курса клинической гастроэнтерологии

eka-pl@rambler.ruGrachevaT. YuГрачеваТ. ЮSBEI HPE Kemerovo State Medical Academy of RMPHГБОУ ВПО «Кемеровская государственная медицинская академия» Минздрава РФ20012016232NO2 (2016)№2 (2016)556226022023Copyright ©; 2016, Bionika MediaCopyright ©; 2016, ООО «Бионика Медиа»2016Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/288619

The main functional disorders of the gastrointestinal tract (GIT) in the practice of internists include functional dyspepsia and irritable bowel syndrome, which often occur in the population. Current pharmacological approaches to the treatment of these diseases are based only on relieving symptoms, resulting in many patients remain unsatisfied and unhappy with their quality of life. In addition, drug treatment approaches are associated with side effects that reduce the benefits of therapy for the patient in terms of treatment outcomes. In addition to diet and lifestyle changes, the most common way to treat functional disorders of the gastrointestinal tract is the use of herbal preparations in the form of individual plants or their combination. Iberogast® is the drug of choice at all stages of the treatment of functional disorders of both upper and lower gastrointestinal tract. Multidirectional therapeutic effects, good tolerability without significant side effects, the possibility of long-term use are the distinctive characteristics of Iberogast®.

Основные функциональные расстройства желудочно-кишечного тракта (ЖКТ), с которыми сталкиваются интернисты, - функциональная диспепсия и синдром раздраженного кишечника - достаточно часто встречаются в популяции. Современные фармакологические подходы к лечению этих заболеваний основаны исключительно на купировании симптомов, в результате многие пациенты остаются неудовлетворенными и недовольными своим качеством жизни. Кроме того, медикаментозные подходы к лечению связаны с побочными эффектами, которые уменьшают пользу терапии для пациента с точки зрения результатов лечения. Помимо диеты и изменения образа жизни самым частым способом лечения функциональных заболеваний ЖКТ является использование фитопрепаратов в виде отдельных растений или в комбинации. Иберогаст® является препаратом выбора на всех этапах лечения функциональных расстройств как верхнего, так и нижнего этажей ЖКТ. Разнонаправленные терапевтические эффекты, хорошая переносимость без значимых побочных эффектов, возможность длительного применения - отличительные характеристики Иберогаста®.

functional disorders of the gastrointestinal tractfunctional dyspepsiairritable bowel syndromephytotherapyIberogast®функциональные расстройства желудочно-кишечного трактафункциональная диспепсиясиндром раздраженного кишечникафитотерапияИберогаст®Маев И.В., Черемушкин С.В. Синдром раздраженного кишечника. Учебно-методическое пособие. М., 2006. 65 с.Пиманов С.И., Силивончик Н.Н. Римский III Консенсус: избранные разделы и комментарии. Пособие для врачей. Витебск, 2006. 160 с.Скворцов В.В., Тумаренко А.В., Одинцов В.В. и др. Диагностика и лечение функциональной (неязвенной) диспепсии. Лечащий врач. 2008;6:22-6.Drossman D.A. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology. 2006;130(5):1377-90.Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Müller-Lissner S.A. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl. 2):43-7.IBS Management Guidelines 2009. What Your Doctor Knows About Treating IBS By Barbara Bradley Bolen. About.com Guide Updated December 05, 2011.Karaman N., Turkay C., Yonem O. Irritable bowel syndrome prevalence in city center of Sivas. Turk. J. Gastroenterology. 2003;14(2):128-31.Celebi S., Acik Y., Deveci S.E., Bahcecioglu I.H., Ayar A., Demir A., Durukan P. Epidemiological features of irritable bowel syndrome in a Turkish urban society. Journal of gastroenterology and hepatology. 2004;19(7):738-43.Hungin A.P., Whorwell P.J., Tack J., Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Alimentary pharmacology & therapeutics. 2003;17(5):643-50.Jones R. Investigating lower bowel symptoms in general practice. BMJ. 1992;304(6841): 1521-22.Hungin A.P., Chang L., Locke G.R., Dennis E.H., Barghout V. Irritable bowel syndrome in the United States: Prevalence, symptom patterns and impact. Aliment. Pharmacol. Ther. 2005;21:1365-75.Hillila M.T., Farkkila M.A. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment. Pharmacol. Ther. 2004;20:339-45.Agreus L., Talley N.J., Svardsudd K., Tibblin G., Jones M.P. Identifying dyspepsia and irritable bowel syndrome: The value of pain or discomfort, and bowel habit descriptors. Scand. J. Gastroenterol. 2000;35:142-51.Boyce P.M., Koloski N.A., Talley N.J. Irritable bowel syndrome according to varying diagnostic criteria: Are the new Rome II criteria unnecessarily restrictive for research and practice? Am. J. Gastroenterol. 2000;95:3176-83.Drossman D.A., Li Z., Andruzzi E., Temple R.D., Talley N.J., Thompson W.G., et al. US householder survey of functional gastrointestinal disorders Prevalence, sociodemography, and health impact. Dig. Dis. Sci. 1993;38:1569-80.Яковенко А.В., Иванов А.Н., Прянишникова А.С., Агафонова Н.А., Яковенко Э.П. Патогенетические подходы в лечении синдрома раздраженного кишечника. Лечащий врач. 2001;7:10-4.Koloski N.A., Talley N.J., Boyce P.M. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am. J. Gastroenterol. 2001;96:1340-49.Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-91.Talley N.J., Dennis E.H., Schettler-Duncan V.A., et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. American J. of Gastroenterology. 2003;98(11):2454-59.Yarandi S.S., Nasseri-Moghaddam S., Mostajabi P., et al. Overlapping gastroesophageal reflux disease and irritable bowel syndrome: increased dysfunctional symptoms. World J. of Gastroenterology. 2010;16(10):1232-38.Пиманов С.И., Руселик Е.А. Диагностика и лечение функциональной диспепсии: уточненные алгоритмы. Consilium Medicum. Прил. Гастроэнтерология. 2010;2:11-7.Ардатская М.Д. Синдром раздраженного кишечника: эпидемиология, этиопатогенез, диагностика и лечебная коррекция. Фарматека. 2010;13:17-23.Katiraei P., Bultron G. Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome. World J.mized controlled trial. JAMA. 1998;280:1585-Grundmann O., Yoon S.L., Moshiree B. Current developments for the diagnosis and treatment of irritable bowel syndrome. Curr. Pharm. Des. 2010;16:3638-45.Ringel Y., Williams R.E., Kalilani L., Cook S.F. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2009;7:68-72; quiz 3.Jones M.P., Keefer L., Bratten J., Taft T.H., Crowell M.D., Levy R., Palsson O. Development and initial validation of a measure of perceived stigma in irritable bowel syndrome. Psychol. Health Med. 2009;14:367-74.Tang Y.R., Yang W.W., Liang M.L., Xu X.Y., Wang M.F., Lin L. Age-related symptom and life quality changes in women with irritable bowel syndrome. World J. of Gastroenterol. 2012;18:7175-83.Mathew P., Bhatia S.J. Pathogenesis and management of irritable bowel syndrome. Trop. Gastroenterol. 2009;30:19-25.Blanchard E.B., Lackner J.M., Jaccard J., Rowell D., Carosella A.M., Powell C., Sanders K., Krasner S., Kuhn E. The role of stress in symptom exacerbation among IBS patients. J. Psychosom. Res. 2008;64:119-28.Mayer E.A., Craske M., Naliboff B.D. Depression, anxiety, and the gastrointestinal system. J. Clin. Psychiatry. 2001;62(Suppl. 8):28-36; discussion 37.Lackner J.M., Ma C.X., Keefer L., Brenner D.M., Gudleski G.D., Satchidanand N., Firth R., Sitrin M.D., Katz L., Krasner S.S., et al. Type, rather than number, of mental and physical comorbidities increases the s everity of symptoms in patients with irritable bowel syndrome. Clin. Gastroenterol.Hepatol. 2013;11:1147-57.Wade P.R., Chen J., Jaffe B., Kassem I.S., Blakely R.D., Gershon M.D. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J. Neurosci. 1996;16: 2352-64.Coates M.D., Mahoney C.R., Linden D.R., Sampson J.E., Chen J., Blaszyk H., Crowell M.D., Sharkey K.A., Gershon M.D., Mawe G.M., et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004;126:1657-64.Jackson J.L., O'Malley P.G., Tomkins G., Balden E., Santoro J., Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am. J. Med. 2000;108:65-72.Gershon M.D. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J. Clin. Gastroenterol. 2005;39:184-93.Kern M.K., Shaker R. Cerebral cortical registration of subliminal visceral stimulation. Gastroenterology. 2002;122:290-98.Kang S.H., Choi S.W., Lee S.J., Chung W.S., Lee H.R., Chung K.Y., Lee E.S., Moon H.S., Kim S.H., Sung J.K., et al. The effects of lifestyle modification on symptoms and quality of life in patients with irritable bowel syndrome: a prospective observational study. Gut. Liver. 2011;5:472-77.Harris L.R., Roberts L. Treatment for irritable bowel syndrome: patients' attitudes and acceptability. BM.C Complem. Altern. Med. 2008;8:65.Langmead L., Chitnis M., Rampton D.S. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm. Bowel. Dis. 2002;8:174-79.Hussain Z., Quigley E.M. Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2006;23:465-71.Yoon S.L., Grundmann O., Koepp L., Farrell L. Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches. Altern. Med. Rev. 2011;16:134-51.Liu J.P., Yang M., Liu Y.X., Wei M., Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 2006;1:CD004116.Kong S.C., Hurlstone D.P., Pocock C.Y., Walkington L.A., Farquharson N.R., Bramble M.G., McAlindon M.E., Sanders D.S. The Incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J. Clin. Gastroenterol. 2005;39:138-41.Yoon S.L., Grundmann O., Koepp L., Farrell L. Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches. Altern. Med. Rev. 2011;16:134-51.Bensoussan A., Talley N.J., Hing M., Menzies R., Guo A., Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a rando mized controlled trial. JAMA. 1998;280:1585-Grundmann O., Yoon S.L. Complementary and alternative medicines in irritable bowel syndrome: An integrative view. World J. Gastroenterol. 2014;20(2):346-62.Wagner H. Multitarget therapy - the future of treatment for more than just functional dyspepsia. Phytomedicine. 2006;13 (Suppl. 5):122-29.Holtmann G., Adam B., Vinson B. Evidence-based medicine and phytotherapy for functional dyspepsia and irritable bowel syndrome: a systematic analysis of evidence for the herbal preparation Iberogast. Wien. Med. Wochenschr., 2004; 54(21-22): 528-34.Allescher H.D., Wagner H. STW 5/Iberogast: multitargetaction for treatment of functional dyspepsia and irritable bowel syndrome. Wien. Med. Wochenschr. 2007;57(13-14):301-7.Rosch W., Liebregts T., Gundermann K.J., Vinson B., Holtmann G. Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5. Phytomedicine. 2006;3(Suppl. 5):114-21.Wegener T., Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogast). Phytomedicine. 2006;3(Suppl. 5):20-35.Rösch W., Vinson B., Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z. Gastroenterol. 2002;40:401-8.von Arnim U., Peitz U., Vinson B., Gundermann K.J., Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am. J. Gastroenterol. 2007; 102:1268-75.Vinson B. Development of Iberogast: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert;2009;167-89.Simmen U., Kelber O., Okpanyi S.N., et al. Binding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine. 2006;13:51-5.Melzer J., Rösch W., Reichling J. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment. Pharmacol. Ther. 2004;20(11-12):1279-87.Madisch A., Holtmann G., Plein K., Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi centre trial. Aliment. Pharmacol. Ther. 2004; 19:271-79.Ottillinger B., Storr M., Malfertheiner P., Allescher H.D. STW 5 (Iberogast®) - a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien. Med. Wochenschr. 2013;163:65-72.Brandt L.J., Chey W.D., Foxx-Orenstein A.E., Schiller L.R., Schoenfeld P.S., Spiegel B.M., Talley N.J., Quigley E.M. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 2009;104 (Suppl. 1):1-35.Buchert D. Wirksamkeit und Verträglichkeit von Iberogast bei Patienten mit gesicherter Non Ulcus Dyspepsie. Z. Phytotherapie. 1994;15(1):45-6.Madisch A., Melderis H., Mayr G. Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie. Z. Gastroenterologie. 2001;39:1-8.Braden B., Caspary W., Börner N. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol. Motil. 2009;21(6):632- 638.Rösch W., Vinson B., Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z. Gastroenterol. 2002; 40(6):401-8.Gundermann K., Godehardt E., Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials. Adv. Ther. 2003 20(1):43-9.Holtmann G., Nandurkar S., Talley N.J., et al. Herbal medicine for the treatment of functional dyspepsia: a systematic review of the literature and meta-analysis. Gastroenterology. 2007;132(4;Suppl. 2; Abstract. W1204).Sassin I., Buchert D. Efficacy and tolerability of the herbal preparation Iberogast® in the therapy of functional dyspepsia. Phytomedicine. 2000;7(Suppl. II):91-2.Klein-Galczinsky C., Sassin I. Anwendungsbeobachtung zur Wirksamkeit und Vertraglichkeit von Iberogast® in der Therapie des Colon irritabile. Phytotherapie an der Schwelle zum neuen Jahrtausend 1999;125(Abstract P25).Raedsch R., Hanisch J., Bock P. Wirksamkeit und Unbedenklichkeit des Phytopharmakons STW 5 versus Metoclopramid oral bei funktioneller Dyspepsie unter Praxisbedinungen. Z. Gastroenterol. 2007;45(10):1041.Gundermann K.J., Vinson B., Hanicke S. Die funktionelle Dyspepsie bei Kindern - eine retrospektive Studie mit einem Phytopharmakon. Pad. 2004;10:1-6.Leichtle K. Experience reports of the application of Iberogast in children. Research report. Steigerwald: Arzneimittelwerk;1999.Vinson B.R., Radke M. The herbal preparation STW 5 for the treatment of functional gastroin testinal diseases in children aged 3-14 years - a prospective non interventional study. Digestive disease week, Chicago, IL, USA. 8 May 2011 (Abstract 523).Layer P., Andresen V., Pehl C. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilitat (DGNM). Z. Gastroenterol. 2011;49:237-93.Malfertheiner P., Holtmann G., Peitz U. Guidelines of the German society of metabolic and digestive diseases for the therapy of dyspepsia. Z. Gastroenterol. 2001;39(11):937-56.